Leveraging neural plasticity for the treatment of amblyopia.

amblyopia critical period excitatory/inhibitory balance metaplasticity neuroplasticity suppression

Journal

Survey of ophthalmology
ISSN: 1879-3304
Titre abrégé: Surv Ophthalmol
Pays: United States
ID NLM: 0404551

Informations de publication

Date de publication:
17 May 2024
Historique:
received: 25 11 2023
revised: 27 04 2024
accepted: 29 04 2024
medline: 20 5 2024
pubmed: 20 5 2024
entrez: 19 5 2024
Statut: aheadofprint

Résumé

Amblyopia is a form of visual cortical impairment that arises from abnormal visual experience early in life. Most often, amblyopia is a unilateral visual impairment that can develop as a result of strabismus, anisometropia, or a combination of these conditions that result in discordant binocular experience. Characterized by reduced visual acuity and impaired binocular function, amblyopia places a substantial burden on the developing child. Although frontline treatment with glasses and patching can improve visual acuity, residual amblyopia remains for most children. Newer binocular-based therapies can elicit rapid recovery of visual acuity and may also improve stereoacuity in some children. Nevertheless, for both treatment modalities full recovery is elusive, recurrence of amblyopia is common, and improvements are negligible when treatment is administered at older ages. Insights derived from animal models about the factors that govern neural plasticity have been leveraged to develop innovative treatments for amblyopia. These novel therapies exhibit efficacy to promote recovery, and some are effective even at ages when conventional treatments fail to yield benefit. Approaches for enhancing visual system plasticity and promoting recovery from amblyopia include altering the balance between excitatory and inhibitory mechanisms, reversing the accumulation of proteins that inhibit plasticity, and harnessing the principles of metaplasticity. Although these therapies have exhibited promising results in animal models, their safety and ability to remediate amblyopia need to be evaluated in humans.

Identifiants

pubmed: 38763223
pii: S0039-6257(24)00046-8
doi: 10.1016/j.survophthal.2024.04.006
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper

Auteurs

Eileen E Birch (EE)

Crystal Charity Ball Pediatric Vision Laboratory, Retina Foundation, Dallas, TX USA; University of Texas Southwestern Medical Center, Dallas, TX USA. Electronic address: ebirch@retinafoundation.org.

Kevin R Duffy (KR)

Department of Psychology and Neuroscience, Dalhousie University, Halifax, NS CANADA.

Classifications MeSH